argenex (NASDAQ:ARGX) Stock Gets Price Target Cut from Guggenheim

argenex (NASDAQ:ARGX) had its price objective dropped by investment analysts at Guggenheim from $1,185.00 to $1,120.00 in a report released on Friday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. Guggenheim‘s target price indicates a potential upside of 28.75% from the company’s previous close.

ARGX has been the subject of a number of other research reports. Citizens Jmp raised their price target on shares of argenex from $932.00 to $1,200.00 and gave the company a “market outperform” rating in a report on Tuesday, August 18th. The Goldman Sachs Group reiterated a “buy” rating on shares of argenex in a research report on Friday, September 25th. Bank of America lifted their target price on argenex from $1,016.00 to $1,088.00 and gave the company a “buy” rating in a research note on Thursday, July 2nd. Jefferies Financial Group reissued a “buy” rating on shares of argenex in a research note on Monday, September 14th. Finally, Robert W. Baird boosted their target price on argenex from $823.00 to $861.00 and gave the stock a “neutral” rating in a research report on Friday. One research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $1,145.53.

argenex Trading Down 0.7%

NASDAQ ARGX traded down $5.89 on Friday, hitting $869.87. 89,926 shares of the company were exchanged, compared to its average volume of 351,696. The firm has a 50 day moving average of $956.17 and a two-hundred day moving average of $885.45. The company has a market cap of $54.71 billion, a P/E ratio of 33.37, a P/E/G ratio of 0.82 and a beta of 0.44. argenex has a 1-year low of $661.85 and a 1-year high of $1,072.75.

argenex (NASDAQ:ARGX) last announced its earnings results on Friday, October 23rd. The company reported $7.80 earnings per share for the quarter, topping analysts’ consensus estimates of $7.44 by $0.36. argenex had a net margin of 32.19% and a return on equity of 43.59%. The company had revenue of $1.75 billion during the quarter. Research analysts anticipate that argenex will post 28.71 EPS for the current fiscal year.

Hedge Funds Weigh In On argenex

Large investors have recently bought and sold shares of the business. Eastern Bank bought a new position in argenex in the second quarter valued at approximately $32,000. Whipplewood Advisors LLC acquired a new stake in argenex during the 1st quarter worth $28,000. Axiom Investment Management LLC acquired a new stake in argenex during the 1st quarter worth $50,000. Mather Group LLC. grew its holdings in argenex by 19.1% during the 3rd quarter. Mather Group LLC. now owns 81 shares of the company’s stock worth $78,000 after acquiring an additional 13 shares during the period. Finally, WPG Advisers LLC raised its position in shares of argenex by 17.8% during the 1st quarter. WPG Advisers LLC now owns 86 shares of the company’s stock valued at $63,000 after acquiring an additional 13 shares during the last quarter. 60.32% of the stock is currently owned by institutional investors and hedge funds.

Key argenex News

Here are the key news stories impacting argenex this week:

• Positive Sentiment: argenx reported third-quarter revenue of approximately $1.75 billion, with product net sales up 54% year over year to $1.7 billion. Earnings of $7.80 per share exceeded the $7.44 consensus estimate, while operating profit reached $486 million, or a 28% margin. Argenx SE Stock Falls Despite $1.7 Billion Sales and Profit Growth
• Positive Sentiment: Jefferies said the recent weakness may create an attractive entry point and maintained a favorable view of argenx’s setup through year-end 2026. Jefferies Analyst Commentary
• Neutral Sentiment: Robert W. Baird raised its price target from $823 to $861 but retained a neutral rating, implying limited upside at the reported share price. Royal Bank of Canada separately cut its target, underscoring mixed analyst sentiment. Robert W. Baird Analyst Ratings RBC Price Target Update
• Negative Sentiment: A surprise testing setback in a VYVGART-related study for Sjögren’s syndrome raised concerns about the breadth and timing of argenx’s pipeline expansion. Because VYVGART is the company’s primary commercial growth driver, the news overshadowed the quarterly earnings beat and strong sales growth. Argenx Testing Setback

About argenex

argenx SE (NASDAQ: ARGX) is a global immunology company focused on developing and commercializing therapies for patients with severe autoimmune diseases. The company uses its antibody engineering capabilities to discover and advance medicines designed to target disease-causing immune mechanisms.

argenx’s lead product is VYVGART (efgartigimod alfa), an antibody fragment that targets the neonatal Fc receptor, or FcRn, to reduce levels of disease-causing immunoglobulin G antibodies. VYVGART is approved in several markets for the treatment of generalized myasthenia gravis.